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Abbreviations 
 
AECC: American-European consensus conference 
ALI:  acute lung injury 
Ang:  angiopoietin  
ARDS: acute respiratory distress syndrome 
ATP:  adenosine triphosphate 
CPAP: continuous positive airway pressure 
CT:  computed tomography 
ECMO: extra corporeal membrane oxygenation 
EVLW: extra vascular lung water 
HES:  hydroxyethyl starch 
HFOV: high frequency oscillatory ventilation 
ICU:  intensive care unit 
IL:  interleukin 
MOF:  multi-organ failure 
NMBA: neuromuscular blocking agent 
OSCAR: high frequency oscillation in ARDS 
OSCILLATE: oscillation for acute respiratory distress syndrome treated early 
PEEP: positive end expiratory pressure 
RBC:  red blood cell 
SIRS:  systemic inflammatory response syndrome 
TNF-a: tumour necrosis factor alpha 
VEGF: vascular endothelial growth factor 
VILI:  ventilator induced lung injury 
vWF:  von willebrand factor 
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Abstract 
 The Acute Respiratory Distress Syndrome (ARDS) is a well-known 
pathology in critical care medicine. ARDS can result from many pulmonary and 
non-pulmonary pathological insults. It is characterised by intractable hypoxia, 
diffuse alveolar damage, accumulation of protein rich alveolar fluid, and it can 
lead to multiple organ failure. The lack of objective clinical diagnostic tests and 
disease specific treatments are the reasons that ARDS remains a clinical 
diagnosis with high mortality. This challenge is met with multi-centre task forces 
assembled specifically to address current practices. Many current treatments and 
diagnostic algorithms, namely the Berlin definition of ARDS, have come from 
such cooperation. Indispensible in the treatment of ARDS is low volume 
mechanical ventilation with avoidance of excessive airway pressures, which is 
know as lung protective ventilation. Its role as well as the role of current 
supportive treatments including: fluid management, extracorporeal membrane 
oxygenation, sedation, neuromuscular blocking agents, and recruitment 
manoeuvres will be discussed.  
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Introduction 
 When the origins of the acute respiratory distress syndrome (ARDS) are 
discussed (1, 2), the study usually mentioned is that of Ashbaugh et al (3). The 
authors observed a similar clinical presentation between an adult population 
receiving respiratory therapy for an acute respiratory syndrome, with the known 
infant respiratory distress syndrome. This acute respiratory disorder was not only 
limited to the lungs in causing: hypoxemia, decreased compliance, and diffuse 
bilateral pulmonary infiltrates, but also existed as a multiple organ insult resulting 
in a high mortality of 58%. Diffuse alveolar damage is a key term regarding the 
pathophysiology of ARDS (4). Protein and inflammatory infiltrates enter the 
alveoli resulting in fluid draw, atelectasis, increased lung weight, decreased 
compliance, and eventually the syndrome culminates with a fibroproliferative 
phase, which can be concurrent with progressing multiple organ failure. The 
causes of ARDS are numerous and diverse. The initial pathological insult 
resulting in ARDS can be from both pulmonary and extra pulmonary causes, with 
direct pulmonary causes being more common (3, 5, 6). The key feature of an 
extra pulmonary cause is the systemic inflammatory response syndrome (SIRS). 
It is proposed that excessive activation of inflammatory and coagulation 
cascades, is essential in terms of lung injury and endothelial-alveolar dysfunction 
which contribute to the development of ARDS. These diverse pathologies create 
a clinical picture that is ARDS, which is defined by the Berlin criteria (7). The 
current criteria for diagnosis include the classic definition of acute lung injury 
(ALI) and ARDS as both ARDS. The removal of the categories of 200 mmHg 
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<PaO2/FiO2 <300 mmHg defining ALI allowed more comprehensive stratifying 
and better predictive value for mortality (7). This is critical as we see that early 
identification and treatment with protective ventilation of ARDS and at risk ARDS 
patients can improve clinical outcomes (8). The current mainstay of treatment is 
supportive care with lung protective mechanical ventilation (8-11). The clinical 
rationale for including classical ALI with ARDS will be discussed with regards to 
the essential initiation of early protective ventilation and ventilator settings 
themselves. Additionally, the current pathophysiological models of ARDS 
development will be discussed, along with current standards of care and 
developing treatments.  
 
Pathophysiology of ARDS 
 Since the original description of ARDS (3), research into its 
pathophysiology using both clinical data and post mortem studies have furthered 
our understanding of the pathophysiology of ARDS. However, ARDS is a very 
diverse pathology that is an important clinical outcome to many pathological 
insults including: sepsis, shock, lung injury, polytrauma, and others insults which 
cause excessive activation of inflammation and coagulation cascades (11-13). 
The key feature of ARDS is damage to the alveolar epithelial and capillary 
endothelial cells, resulting in increased permeability. This cellular damage can 
result from direct pulmonary insults such as pneumonia, or from various 
extrapulmonary insults. 
 The Berlin definition of ARDS clinically classifies the disorder into mild 
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(200 mmHg < PaO2/FiO2 < 300mmHg), moderate (100 mmHg < PaO2/FiO2 > 
200mmHg), and severe (PaO2/FiO2 <100 mmHg) categories (7). There must be 
additional requirements met in order for these ratios to be accurate in stratifying 
patients. Invasive mechanical ventilation must be used with positive end 
expiratory pressure (PEEP) of at least 5 cmH2O, with the exception of mild 
ARDS where continuous positive airway pressure (CPAP) can be used. Imaging 
should demonstrate opacities not explained by effusions, collapse or nodules (7, 
14). The origin of lung oedema should not be from cardiac failure or from fluid 
overload (7, 14). These criteria should be established within 1 week of a known 
clinical insult or after new/rapidly worsening respiratory symptoms (7). While 
extensive and specific, the criteria outlined by the Berlin definition of ARDS allow 
for a better predictive validity for mortality, when compared with the older clinical 
criteria for ARDS, the American-European Consensus Conference (AECC) 
criteria (7).       
 While there is evidence that patients maintaining maximum lung fluid 
clearance have lower mortality and a shorter duration of mechanical 
ventilation(15), extra vascular lung water (EVLW) by itself is not a cause of 
ARDS, nor an independent predictor for mortality (15). This was a diagnostic 
criteria utilised before the Berlin definition was posed, which was subsequently 
removed as hydrostatic oedema is not a primary cause of respiratory failure (7). 
The key component in the pathology of ARDS appears to be capillary endothelial 
and alveolar epithelial damage, which allows protein rich fluid to accumulate in 
the alveoli with subsequent ability to clear such fluid being impaired (16). 
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Proteinaceous intra-alveolar fluid accumulation results in increased lung weight, 
atelectasis, impaired surfactant production, shunt, and further damage to the 
alveoli (15, 17). Decreased compliance, hypoxia and increased pressure required 
in mechanical ventilation are then to be expected. When a sufficient amount of 
lung parenchyma is involved, pulmonary hypertension also occurs which can 
potentially lead to right heart dysfunction. The progression of ARDS, beginning 
with diffuse alveolar damage, follows through three phases consisting of: 
exudation, fibroproliferation (proliferation) and resolution (4). The initial exudative 
phase corresponds to the Berlin criteria regarding deterioration in lung function 
with refractory hypoxemia (7, 13). A significant pulmonary or extrapulmonary 
pathology resulting in damage to the alveolar-capillary interface causes fluid, as 
well as cell material, proteins and inflammatory mediators to begin accumulating 
in alveolar spaces. The specific inflammatory mediators involved are numerous 
and remain a topic of investigation in order to further elucidate the 
pathophysiology of ARDS in addition to the search for diagnostic ARDS 
biomarkers (18-20). Migration of neutrophils to the alveoli also occurs, followed 
by histone release, an important cause of endothelial damage (21). After loss of 
epithelial cells and capillary endothelium, protein rich fluid fills the alveoli and in 
combination with cellular debris, cumulates in forming hyaline membranes (7, 
22). The resultant clinical effects of the exudative phase are: decreasing effective 
lung surface area, decreasing compliance, and increase in shunt, which results in 
increased work of breathing. Injury to type 2 alveolar cells also results in 
decreased surfactant production (17), which further exacerbates the changes in 
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lung compliance, and represents a challenge for mechanical ventilation. Higher 
inspiratory pressures are then required to achieve alveolar opening. Overlapping 
with the exudative phase is the fibroproliferative phase. During this phase there is 
repopulation of type2 alveolar cells, fibroblast and myofibroblast proliferation as 
well as matrix deposition (23). The alveolar fluid resembles a more protein rich 
composition as oedema resolution occurs, due to type 2 alveolar basal Na/K 
ATPase dependent removal of fluid (15, 23). The proportion that the resulting 
fibrosis (and its potential recovery) owes to the damage of: pulmonary epithelium, 
capillary endothelium and degree of inflammatory processes during the ARDS is 
unclear and is also being discussed with respect to pulmonary and extra 
pulmonary causes (23). The majority of ARDS non-survivors show higher 
degrees of: capillary thrombosis, lung fibrosis and neovascularization (1). 
Approximately 60% of ARDS deaths occur within the first 14 days after diagnosis 
(11). However, the majority of ARDS deaths seem not to be attributed directly to 
the presence of a fibrotic lung or hypoxemia, but rather to multi organ failure 
(MOF) from a systemic inflammatory response syndrome (SIRS) due to the lung 
injury (2, 11).  
 Various extrapulmonary insults can result in ARDS, such as: trauma, 
pancreatitis, major trauma, burns, and haemorrhage (22, 24). These insults 
cause SIRS, which is associated with a systemic cytokine storm, cell damage 
and tissue injury. The aggressive inflammatory response causes injury to the 
pulmonary capillary endothelium, which initiates the acute phase of ARDS (23). 
As with the pulmonary insult, this endothelial damage also allows protein rich 
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oedema fluid accumulation within the alveoli. Concurrently, pro-inflammatory 
cytokines are released, and neutrophils are recruited, which continue to release 
toxic mediators, furthering free radical production and diffuse alveolar damage 
(13). In extraplumonary insults, it appears that ARDS is part of the multi organ 
damage associated with an excessive inflammatory response. The diagnosis of 
ARDS as well as findings on imaging for non-pulmonary insults, are as described 
for pulmonary insults (7). 
 
Treatment 
 With the continuing exposure to ARDS in the ICU, physicians are 
continuing to advance current treatments. Also, new treatments and novel 
approaches are being currently researched. The existing standard treatments as 
well as possible future treatments for ARDS will be discussed. 
 
Mechanical ventilation 
 Since the utilisation of mechanical ventilation is required to pose a 
diagnosis of ARDS as per the Berlin criteria (7), it is only fitting that it be used as 
the mainstay of treatment in ARDS. In ARDS the increased lung weight, 
decreased compliance and increased work of breathing leads to refractory 
hypoxia in the patient (7, 13). Supplemental oxygen and positive pressure 
ventilation combat this deficit. While mechanical ventilation is universally 
accepted as a life saving intervention it is not without it’s hazards. Over 
ventilation, namely using plateau pressures of greater than 30 cmH2O and high 
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tidal volumes have been recognised as precipitators of further lung injury (10, 25, 
26). In ARDS, parenchyma elasticity is heterogeneous due to collapsed alveoli, 
increased EVLW, inflammation, and liquid plugs in conducting airways (10). 
There are three populations of alveoli in the lung model of ARDS (10): normal 
functioning alveoli, collapsed alveoli capable of opening with higher inspiratory 
pressures (recruitable), and collapsed non-recruitable alveoli. The “baby lung” 
concept describes the phenomenon of decreased available lung for ventilation 
(10) mainly due to lung heterogeneity. In this model, the normal functioning 
alveoli over distend during standard tidal volumes of 10-12 ml/kg in 
compensation of additional tidal volume from alveoli lost due to collapse (9). The 
resulting over stretch of the alveoli is referred to as volutrauma, and is the main 
cause of ventilator associated lung injury (9, 10, 27). Additionally, the repeated 
opening and closing of recruitable alveoli during ventilation, know as 
atelectrauma (28), results in further lung damage and increased lung 
heterogeneity (29). These two mechanisms of lung injury by mechanical 
ventilation are know collectively as ventilator induced lung injury (VILI) (28). VILI 
propagates further lung injury and alveolar collapse. This increased lung injury is 
hypothesised to increase neutrophil recruitment and inflammatory mediator 
release, which is known as biotrauma (9, 28). This is presumably one of the 
causes of MOF occurring in ARDS patients (28), as well as an explanation why 
mortality is higher in standard versus lung protective ventilation (9). In a major 
meta-analysis of twenty articles examining lung protective ventilation, 6-8 ml/kg 
were used as tidal volumes (9). Using low volume protective ventilation, in 
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conjunction with PEEP to increase alveoli recruitment, combats the refractory 
hypoxia seen in ARDS. The current accepted standard of therapy in mechanical 
ventilation for ARDS is using a target tidal volume of 6ml/kg and supplemental 
PEEP while maintaining plateau pressure <30cmH2O (25, 30, 31). However, with 
early studies applying these principles being conflicting (32, 33), further research 
and major centre trials were needed. One of the first major multi-centre studies 
on lung protective ventilation to show decrease in mortality was stopped after 
enrolling 861 patients as the difference in mortality from traditional ventilation 
was 31.0% vs. 39.8% P=0.007 (34). Results of lung protective ventilation have 
even warranted their use during non ARDS ventilation, such as in the operating 
theatre and in the general ICU population (9, 27, 30). There exists the potential 
for volutrauma during ventilation, therefore plateau pressure, comprised of PEEP 
and the pressure required to deliver tidal volumes, must be monitored, as using 
plateau pressures below 30 cmH2O is associated with a survival benefit (9). 
While mechanical ventilation is a potential cause for lung injury (27), low tidal 
volume ventilation in ARDS is an essential treatment protocol (7, 25).   
 High frequency oscillatory ventilation (HFOV) is ventilation using pressure 
oscillations to deliver tidal volumes with a relatively constant mean airway 
pressure (mPaw) at rates of 3-15 Hz (28). The result is small tidal volumes of 1-3 
ml/kg around a “safe” area of the volume pressure curve (35), which theoretically 
avoids overdistension and atelectrauma. The use of low tidal volumes around a 
constant pressure is also intended to minimise the hemodynamic effects of 
mechanical ventilation. The device system used in adults is typically a membrane 
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diaphragm style, capable of oscillating to produce small volume displacements at 
high frequencies. Unlike in conventional ventilation, HFOV achieves adequate 
gas exchange with tidal volumes less than anatomic dead space. Gas transport 
is achieved by convective and diffusive mechanisms in the airways which causes 
gas mixing that is sufficient for exchange at the alveoli (36, 37). Although within 
normal physiology, tidal volume is more important than frequency in determining 
elimination of CO2, the ARDS lung is reliant more on frequency for CO2 
elimination (35). With the potential of avoiding VILI in ARDS, HFOV became an 
attractive option in the ICU as an adjuvant to standard mechanical ventilation 
protocols. Initial studies showed potential promise in using HFOV, by 
demonstrating benefits to oxygenation and survival when compared to controls 
(38, 39). These studies however had small sample sizes and had utilised less 
than current ventilation protocols for their control groups. Two major studies set 
out to investigate the potential benefits of HFOV in ARDS treatment, which were 
the OSCILLATE trial (40) and the OSCAR trial (41). The OSCILLATE trial was a 
multi-centre randomised trial performed in 39 intensive care units in 5 countries. 
Regarding moderate to severe ARDS, they found that HFOV compared to lung 
protective ventilation was associated with no survival benefit, but rather an 
increase in mortality (47% to 35% in controls, CI 1.09-1.64, P=0.005) (40). The 
study was terminated early due to these preliminary findings. The OSCAR trial, 
performed in 12 university intensive care units, found that using 30 day all cause 
mortality as an end point, showed no significant difference between the HFOV 
and control (lung protective ventilation) groups (41). With the failure of studies to 
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effectively demonstrate a benefit for HFOV against current lung protective 
ventilation (38, 39), and with major randomised studies demonstrating either no 
benefit (41) or increased mortality (40), ARDS (and even non-ARDS) ventilation 
protocol remains as low tidal volume lung protective ventilation (9). 
 
Extracorporeal Membrane Oxygenation 
 ECMO is a: venous-venous, arterial-venous (pumpless) or venous-arterial 
assist bypass device, which oxygenates and removes CO2 from blood and can 
be a partial cardiac assist device when used as venous-arterial oxygenation 
device (42). While requiring concomitant use of heparin to prevent clotting, these 
devices can deliver oxygen (3ml/kg/min) and remove CO2 (3-6ml/kg/min) to meet 
normal metabolic demands (42). The device can even serve as partial support, 
where its function is restricted to CO2 removal. With use of the ECMO system, 
expected patient complications include: bleeding, hemolysis, coagulation, clotting 
in the ECMO circuit, and thrombocytopenia (43). The use of ECMO has 
increased, notably during the H1N1 pandemic, however large randomised clinical 
trials investigating benefits to mortality are still lacking (44). Specifically with 
regards to ARDS, ECMO is being investigated as a means to further prevent 
VILI. While lung protective ventilation in ARDS constitutes using tidal volumes of 
6ml/kg, there is evidence that even these volumes produce alveolar 
overdistension, which can be demonstrated on CT (45). A treatment approach 
currently being investigated with respect to ECMO is the use of a minimally 
invasive veno-venous (or arterial-venous pumpless) CO2 removal unit combined 
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with ultra-protective lung ventilation (<3ml/kg) to further avoid VILI (46, 47). 
Clinical outcomes were improved in ARDS patients when tidal volume was 
limited to <3ml/kg combined with pumpless arterial-venous ECMO to eliminate 
excessive carbon dioxide (46). While additional research is needed for the role of 
ECMO in ARDS, it is possible that it will become an adjuvant in the progression 
towards lower tidal volumes for the protection against VILI. 
 
Lung Recruitment 
While the use of low tidal volume ventilation with moderate PEEP ensuring 
plateau pressures less than 30 cmH2O is commonly used in ARDS, other 
ventilator strategies, physical manoeuvres, and even pharmacological treatments 
have been investigated to increase lung recruitment. Lung recruitment is the 
attempt to increase lung homogeneity and decrease VILI by opening recruitable 
alveoli and prevent their closure. The benefits to successful recruitment are: 
improved oxygenation, decreased VILI, and more accurate ventilation-perfusion 
matching (8). A number of methods exist in terms of recruitment manoeuvres. 
Short term increases in PEEP with higher lung volumes called “sighs” have been 
frequently employed (29). The results of this technique however, are not 
significant and result only in short term differences in oxygenation (29, 48). 
HFOV has also been used as a recruitment manoeuvre, yet it lacks any benefit in 
terms of improvements against mortality or clinical outcomes (40, 41). Various 
chest wall modification strategies to increase trans-pulmonary pressure have 
been investigated such as: abdominal decompression, regular pleural effusion 
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drainage, and allowing spontaneous breathing. However these methods have not 
gained sufficient promise to be utilised as standard treatments (7, 29). Prone 
positioning has been used to increase trans pulmonary pressure in the dorsal 
lung regions to create a regional PEEP effect in addition to improvements in 
ventilation-perfusion mismatching (29, 49, 50).     
 Prone positioning is being used in severe ARDS as a recruitment 
manoeuvre, and meta-analyses have already demonstrated improvements in 
oxygenation (51, 52). This improved oxygenation is attributed to increase in 
ventilation of perfused areas, therefore improving the ventilation-perfusion 
mismatch seen in ARDS (8). Additional benefits of prone positioning appear to be 
reduction in VILI. There is demonstrated reduction in lung stress-strain and lung 
concentration of pro-inflammatory cytokines (53), as well as in the amount of 
over distended lung areas, which can be demonstrated on CT (54). The 
reduction in stress-strain of the lung and the associated VILI is an important 
pathophysiological modification in severe ARDS. In addition to improved 
oxygenation and decreased amount of pro-inflammatory cytokines, which can 
affect systemic organ function, prone positioning may influence alveolar fluid 
clearance. The prevention of lung injury (53) spares alveolar epithelium which is 
associated with increased fluid clearance and better clinical outcomes (15). 
Taken together, these pathophysiological rationales of prone positioning support 
its clinical use in the treatment of ARDS. Additionally there is a demonstrated 
reduction in mortality using prone positioning in severe ARDS (49, 55), likely 
attributed to these and possibly other pathophysiological benefits.  
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Fluid Management 
 As with all ICU patients, fluid management is crucial. In ARDS however, it 
becomes more complex as there exists increased lung permeability, which 
results in alveolar fluid accumulation due to epithelial and endothelial damage 
(15). Additionally, extrapulmonary causes of ARDS often are due to sepsis, 
which globally increases vascular permeability (11-13). Intuitively, the approach 
to fluid management in ARDS would be to prevent over hydration to avoid 
excessive fluid leak, yet allow sufficient end organ perfusion. A major ARDS 
Network trial found that although no significant 60 day mortality difference was 
found between the fluid conservative and fluid liberal approaches, improved lung 
function and shorter duration of mechanical ventilation were seen in the fluid 
conservative group (56). Although extrapulmonary versus pulmonary causes for 
ARDS were not recorded, the researchers noted that fluid balance in the fluid 
liberal approach was similar to fluid balance in studies without strict fluid 
protocols, thus reflecting current fluid practices in the two ARDS causes (56). 
While there are pulmonary and extrapulmonary insults leading to ARDS, a large 
degree of patients have a sepsis related ARDS (57). This is important when 
considering the type and degree of fluid management in ARDS. The question of 
using crystalloids versus hydroxyethyl starch (HES) colloids has been extensively 
studied (50, 58, 59). A major review and meta analysis of literature concerning 
this question showed increased risk of renal replacement therapy, RBC 
transfusion, and severe adverse reactions when using HES in patients with 
sepsis (60). Initial fluid management in ARDS should follow surviving sepsis 
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guidelines (61, 62) without precipitating an excessive fluid balance as it is 
associated with poor outcomes (63). Additionally in ARDS, with or without sepsis, 
alveolar fluid clearance is impaired and increased EVLW is associated with 
poorer outcomes (15). Sepsis resulting in ARDS was associated with more 
severe impairment of alveolar fluid clearance, and this clearance was not 
affected by administration of catecholamines, dopamine or corticosteroids (15).  
 
Pharmacological Treatments 
 Neuromuscular blocking agents (NMBA) have been employed in the 
treatment of ARDS. Most frequently they are used in conjunction with sedation to 
facilitate patient-ventilator synchrony (64). Asynchrony of ventilation can result in 
increased airway pressures, which is associated with barotrauma and VILI (65). 
When attempting to control increased airway pressures or increase lung 
recruitment with the prone position, NMBA’s are used (66). A risk of NMBA use is 
muscle weakness and ventilator dependence. However, Papazian et al (67) 
found that early use of cistracurium in severe (<150 PaO2/FiO2) ARDS improved 
90 day survival and increased time off the ventilator without increasing muscle 
weakness. Additionally, the study found no difference in gas exchange between 
treatment and placebo groups (67). It is proposed that the beneficial effects of 
NMBAs in this context is due to an anti-inflammatory property via their interaction 
with the nicotinic acetylcholine receptors, in addition to improving ventilator 
synchrony with the patient to avoid VILI (65). While lung protective effects have 
been seen with NMBAs, further studies are needed to confirm the benefits and 
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examine the mechanisms of their actions. 
 While corticosteroids are avoided in sepsis treatment guidelines, unless 
underlying shock is present (62), they have been under investigation for use in 
ARDS (68-70). Two mechanisms are proposed for the actions of corticosteroids 
based on their dosages. At low doses (<2.5mg/kg/day) they act at the level of the 
nucleus to increase anti-inflammatory mediator transcription, and inhibit pro-
inflammatory mediators (71). High doses (>30mg/kg/day) show non-genomic 
effects at the cell surface to inhibit neutrophil degranulation (72, 73). In extensive 
examination of the literature concerning ARDS and corticosteroid use, low 
dosage shows potential lung function improvement and less time spent on 
mechanical ventilation, yet high dosage use is considered harmful (70). The 
impact of low doses on long term mortality is unclear (70). Some research 
indicates there is no benefit to its use (74), while other research indicates 
associations between corticosteroid use and the development of neuromyopathy 
(75, 76). Therefore further investigation is required before corticosteroids are 
widely accepted as an ARDS treatment. 
 Sedation use in ARDS facilitates ventilator-patient synchrony, patient 
comfort and somnolence, lower opioid use, and is necessary for mechanical 
ventilation. Its overuse can precipitate ventilator dependence, longer ICU stay 
and potential for brain dysfunction (77). Research is suggesting that regular 
sedation interruption versus continuous sedation can combat these side effects 
and lead to increases in ventilator free days (77, 78). An emerging sedative, 
dexmedetomidine, reduces duration of mechanical ventilation compared to 
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midazolam and propofol, and avoids propofol infusion syndrome (79). This a-2 
adrenergic agonist causes central sedation and analgesia without significant 
respiratory depression (79). This lack of respiratory depression possibly aids in 
eventual ventilator weaning. It has been reported that use of dexmedetomidine is 
associated with more adverse events in comparison with midazolam or propofol 
(79).         
 
Biomarkers 
 There are many proteins and inflammatory markers associated with 
ARDS. Notable proteins include: TNF-a, IL-6, IL-8, protein C, von Willebrand 
factor (vWF), and vascular endothelial growth factor (VEGF). The isolation of a 
specific biomarker for ARDS would provide an objective indication of disease 
status. There has been extensive research and review in the search for ARDS 
biomarkers, notably with cytokines (19, 20, 47, 80). The interest in using 
inflammatory cytokines as biomarkers arose from correlations between IL-1b, 
TNF-a, and ARDS mortality (20, 81). The challenge with using cytokines as 
ARDS specific biomarkers is the heterogeneity of ARDS causes. This is 
demonstrated by the lack of IL-1b and TNF-a in trauma patients with ARDS (82, 
83). IL-6 additionally, correlates with ARDS development in diverse ICU patients 
but shows inconsistent association with trauma associated ARDS (82, 83). With 
the multitude of cytokines associated with ARDS, it appears there are differences 
in their expression regarding different causes of ARDS. Their overlapping 
expression also compounds the possibility of using them as a disease specific 
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biomarker. 
 Endothelial proteins Ang-1 and Ang-2 are markers of endothelial health 
and dysfunction respectively. Ang-2’s has been studied in sepsis as a therapeutic 
target and disease marker (84, 85). Levels of Ang-2 or ratio of Ang-2/Ang-1 
correlates with mortality in sepsis and also represents endothelial health (85). 
Increased Ang-2 levels have been demonstrated in ARDS (18, 86, 87), and show 
a correlation with mortality (18). Additionally, trauma patients have shown 
correlations between Ang-2 levels and the development of ARDS (88). With 
endothelial dysfunction being a key feature of ARDS, further research with Ang-2 
could show promise in identifying patients who are at risk of ARDS and in 
predicting mortality of patients with ARDS.  
 The challenge with obtaining an ARDS specific biomarker is that ARDS 
represents a syndrome rather than a single disease entity. Thus finding a specific 
biomarker to predict ARDS development, severity, and mortality remains a 
daunting task. It is possible however that a combination of markers could be 
used to aid in predicting ARDS outcome.    
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Conclusion 
 ARDS remains an important cause of mortality in the ICU. Lung protective 
ventilation is the mainstay of treatment, along with supportive measures. ECMO, 
prone positioning and pharmaceuticals are adjuvants to mechanical ventilation. 
There is no unique treatment protocol for ARDS from pulmonary versus extra-
pulmonary causes. Objective tests are still under investigation and ARDS 
remains a clinical diagnosis, supported by imaging. Additional multi-centre 
clinical trials are needed to expand on treatment protocols in order to decrease 
the mortality from ARDS. 
 
	  	  24	  
Acknowledgements 
I would like to thank Professor Mladen Perić for his mentorship during this 
paper, the late Jon Lord for keeping up my morale during my studies, and finally I 
would like to thank my parents Oskar and Debbie for their continued support.
	  	  25	  
References: 
 1.	   Villar	  J.	  What	  is	  the	  acute	  respiratory	  distress	  syndrome?	  Respiratory	  care.	  2011;56(10):1539-­‐45.	  
2.	   Villar	  J,	  Sulemanji	  D,	  Kacmarek	  R.	  The	  acute	  respiratory	  distress	  syndrome:	  incidence	  and	  mortality,	  has	  it	  changed?	  Current	  opinion	  in	  critical	  care.	  2014;20(1):3-­‐9.	  
3.	   Ashbaugh	  D,	  Bigelow	  D,	  Petty	  T,	  Levine	  B.	  Acute	  respiratory	  distress	  in	  adults.	  Lancet.	  1967;2(7511):319-­‐23.	  
4.	   Tomashefski	  J.	  Pulmonary	  pathology	  of	  acute	  respiratory	  distress	  syndrome.	  Clinics	  in	  chest	  medicine.	  2000;21(3):435-­‐66.	  
5.	   Matthay	  M,	  Zimmerman	  G.	  Acute	  lung	  injury	  and	  the	  acute	  respiratory	  distress	  syndrome:	  four	  decades	  of	  inquiry	  into	  pathogenesis	  and	  rational	  management.	  American	  journal	  of	  respiratory	  cell	  and	  molecular	  biology.	  2005;33(4):319-­‐27.	  
6.	   Spragg	  R,	  Bernard	  G,	  Checkley	  W,	  Curtis	  J,	  Gajic	  O,	  Guyatt	  G,	  et	  al.	  Beyond	  mortality:	  future	  clinical	  research	  in	  acute	  lung	  injury.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2010;181(10):1121-­‐7.	  
7.	   Force	  ADT,	  Ranieri	  V,	  Rubenfeld	  G,	  Thompson	  B,	  Ferguson	  N,	  Caldwell	  E,	  et	  al.	  Acute	  respiratory	  distress	  syndrome:	  the	  Berlin	  Definition.	  JAMA	  :	  the	  journal	  of	  the	  American	  Medical	  Association.	  2012;307(23):2526-­‐33.	  
8.	   Guérin	  C.	  Prone	  position.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):92-­‐7.	  
9.	   Neto	  A,	  Cardoso	  S,	  Manetta	  J,	  Pereira…	  V.	  Association	  between	  use	  of	  lung-­‐protective	  ventilation	  with	  lower	  tidal	  volumes	  and	  clinical	  outcomes	  among	  patients	  without	  acute	  respiratory	  distress	  syndrome:	  a	  ….	  Jama.	  2012.	  
10.	   Suki	  B,	  Hubmayr	  R.	  Epithelial	  and	  endothelial	  damage	  induced	  by	  mechanical	  ventilation	  modes.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):17-­‐24.	  
	  	  26	  
11.	   Villar	  J,	  Blanco	  J,	  Añón	  J,	  Santos-­‐Bouza	  A,	  Blanch	  L,	  Ambrós	  A,	  et	  al.	  The	  ALIEN	  study:	  incidence	  and	  outcome	  of	  acute	  respiratory	  distress	  syndrome	  in	  the	  era	  of	  lung	  protective	  ventilation.	  Intensive	  care	  medicine.	  2011;37(12):1932-­‐41.	  
12.	   Pierrakos	  C,	  Karanikolas	  M,	  Scolletta	  S,	  Karamouzos	  V,	  Velissaris	  D.	  Acute	  respiratory	  distress	  syndrome:	  pathophysiology	  and	  therapeutic	  options.	  Journal	  of	  clinical	  medicine	  research.	  2012;4(1):7-­‐16.	  
13.	   Ware	  L,	  Matthay	  M.	  The	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2000;342(18):1334-­‐49.	  
14.	   Barbas	  C,	  Isola	  A,	  Caser	  E.	  What	  is	  the	  future	  of	  acute	  respiratory	  distress	  syndrome	  after	  the	  Berlin	  definition?	  Current	  opinion	  in	  critical	  care.	  2014;20(1):10-­‐6.	  
15.	   Ware	  L,	  Matthay	  M.	  Alveolar	  fluid	  clearance	  is	  impaired	  in	  the	  majority	  of	  patients	  with	  acute	  lung	  injury	  and	  the	  acute	  respiratory	  distress	  syndrome.	  American	  journal	  of	  respiratory	  and	  critical	  ….	  2001.	  
16.	   Martin	  T.	  Lung	  cytokines	  and	  ARDS:	  Roger	  S.	  Mitchell	  Lecture.	  Chest.	  1999;116(1	  Suppl).	  
17.	   Greene	  K,	  Wright	  J,	  Steinberg	  K,	  Ruzinski	  J,	  Caldwell	  E,	  Wong	  W,	  et	  al.	  Serial	  changes	  in	  surfactant-­‐associated	  proteins	  in	  lung	  and	  serum	  before	  and	  after	  onset	  of	  ARDS.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  1999;160(6):1843-­‐50.	  
18.	   Agrawal	  A,	  Matthay	  M,	  Kangelaris	  K,	  Stein	  J,	  Chu	  J,	  Imp	  B,	  et	  al.	  Plasma	  angiopoietin-­‐2	  predicts	  the	  onset	  of	  acute	  lung	  injury	  in	  critically	  ill	  patients.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2013;187(7):736-­‐42.	  
19.	   Binnie	  A,	  Tsang	  J,	  dos	  Santos	  C.	  Biomarkers	  in	  acute	  respiratory	  distress	  syndrome.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):47-­‐55.	  
20.	   Meduri	  G,	  Headley	  S,	  Kohler	  G,	  Stentz	  F,	  Tolley	  E,	  Umberger	  R,	  et	  al.	  Persistent	  elevation	  of	  inflammatory	  cytokines	  predicts	  a	  poor	  outcome	  in	  ARDS.	  Plasma	  IL-­‐1	  beta	  and	  IL-­‐6	  levels	  are	  consistent	  and	  efficient	  predictors	  of	  outcome	  over	  time.	  Chest.	  1995;107(4):1062-­‐73.	  
	  	  27	  
21.	   Mantovani	  A,	  Cassatella	  M,	  Costantini	  C,	  Jaillon	  S.	  Neutrophils	  in	  the	  activation	  and	  regulation	  of	  innate	  and	  adaptive	  immunity.	  Nature	  reviews	  Immunology.	  2011;11(8):519-­‐31.	  
22.	   Matthay	  M,	  Ware	  L,	  Zimmerman	  G.	  The	  acute	  respiratory	  distress	  syndrome.	  The	  Journal	  of	  clinical	  investigation.	  2012;122(8):2731-­‐40.	  
23.	   Rocco	  P,	  Dos	  Santos	  C,	  Pelosi	  P.	  Lung	  parenchyma	  remodeling	  in	  acute	  respiratory	  distress	  syndrome.	  Minerva	  anestesiologica.	  2009;75(12):730-­‐40.	  
24.	   Cauwels	  A,	  Rogge	  E,	  Vandendriessche	  B,	  Shiva	  S,	  Brouckaert	  P.	  Extracellular	  ATP	  drives	  systemic	  inflammation,	  tissue	  damage	  and	  mortality.	  Cell	  death	  &	  disease.	  2014;5.	  
25.	   Ferguson	  N,	  Fan	  E,	  Camporota	  L,	  Antonelli	  M,	  Anzueto	  A,	  Beale	  R,	  et	  al.	  The	  Berlin	  definition	  of	  ARDS:	  an	  expanded	  rationale,	  justification,	  and	  supplementary	  material.	  Intensive	  care	  medicine.	  2012;38(10):1573-­‐82.	  
26.	   Baudouin	  S.	  Ventilator	  induced	  lung	  injury	  and	  infection	  in	  the	  critically	  ill.	  Thorax.	  2001;56(suppl	  2).	  
27.	   Serpa	  Neto	  A,	  Nagtzaam	  L,	  Schultz	  M.	  Ventilation	  with	  lower	  tidal	  volumes	  for	  critically	  ill	  patients	  without	  the	  acute	  respiratory	  distress	  syndrome:	  a	  systematic	  translational	  review	  and	  meta-­‐analysis.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):25-­‐32.	  
28.	   Goffi	  A,	  Ferguson	  N.	  High-­‐frequency	  oscillatory	  ventilation	  for	  early	  acute	  respiratory	  distress	  syndrome	  in	  adults.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):77-­‐85.	  
29.	   Keenan	  J,	  Formenti	  P,	  Marini	  J.	  Lung	  recruitment	  in	  acute	  respiratory	  distress	  syndrome:	  what	  is	  the	  best	  strategy?	  Current	  opinion	  in	  critical	  care.	  2014;20(1):63-­‐8.	  
30.	   Ferguson	  ND.	  Low	  tidal	  volumes	  for	  all?	  JAMA.	  2012;308(16):1689-­‐90.	  
31.	   Hager	  D,	  Krishnan	  J,	  Hayden	  D,	  Brower	  R,	  Network	  ACT.	  Tidal	  volume	  reduction	  in	  patients	  with	  acute	  lung	  injury	  when	  plateau	  pressures	  are	  not	  high.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2005;172(10):1241-­‐5.	  
	  	  28	  
32.	   Amato	  M,	  Barbas	  C,	  Medeiros	  D,	  Magaldi	  R,	  Schettino	  G,	  Lorenzi-­‐Filho	  G,	  et	  al.	  Effect	  of	  a	  protective-­‐ventilation	  strategy	  on	  mortality	  in	  the	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  1998;338(6):347-­‐54.	  
33.	   Brochard	  L,	  Roudot-­‐Thoraval	  F,	  Roupie	  E,	  Delclaux	  C,	  Chastre	  J,	  Fernandez-­‐Mondéjar	  E,	  et	  al.	  Tidal	  volume	  reduction	  for	  prevention	  of	  ventilator-­‐induced	  lung	  injury	  in	  acute	  respiratory	  distress	  syndrome.	  The	  Multicenter	  Trail	  Group	  on	  Tidal	  Volume	  reduction	  in	  ARDS.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  1998;158(6):1831-­‐8.	  
34.	   Ventilation	  with	  lower	  tidal	  volumes	  as	  compared	  with	  traditional	  tidal	  volumes	  for	  acute	  lung	  injury	  and	  the	  acute	  respiratory	  distress	  syndrome.	  The	  Acute	  Respiratory	  Distress	  Syndrome	  Network.	  The	  New	  England	  journal	  of	  medicine.	  2000;342(18):1301-­‐8.	  
35.	   Hager	  D,	  Fessler	  H,	  Kaczka	  D,	  Shanholtz	  C,	  Fuld	  M,	  Simon	  B,	  et	  al.	  Tidal	  volume	  delivery	  during	  high-­‐frequency	  oscillatory	  ventilation	  in	  adults	  with	  acute	  respiratory	  distress	  syndrome.	  Critical	  care	  medicine.	  2007;35(6):1522-­‐9.	  
36.	   dos	  Santos	  C,	  Slutsky	  A.	  Overview	  of	  high-­‐frequency	  ventilation	  modes,	  clinical	  rationale,	  and	  gas	  transport	  mechanisms.	  Respiratory	  care	  clinics	  of	  North	  America.	  2001;7(4):549-­‐75.	  
37.	   Slutsky	  A,	  Drazen	  J.	  Ventilation	  with	  small	  tidal	  volumes.	  The	  New	  England	  journal	  of	  medicine.	  2002;347(9):630-­‐1.	  
38.	   Bollen	  C,	  van	  Well	  G,	  Sherry	  T,	  Beale	  R,	  Shah	  S,	  Findlay	  G,	  et	  al.	  High	  frequency	  oscillatory	  ventilation	  compared	  with	  conventional	  mechanical	  ventilation	  in	  adult	  respiratory	  distress	  syndrome:	  a	  randomized	  controlled	  trial	  [ISRCTN24242669].	  Critical	  care	  (London,	  England).	  2005;9(4):9.	  
39.	   Derdak	  S,	  Mehta	  S,	  Stewart	  T,	  Smith	  T,	  Rogers	  M,	  Buchman	  T,	  et	  al.	  High-­‐frequency	  oscillatory	  ventilation	  for	  acute	  respiratory	  distress	  syndrome	  in	  adults:	  a	  randomized,	  controlled	  trial.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2002;166(6):801-­‐8.	  
40.	   Ferguson	  N,	  Cook	  D,	  Guyatt	  G,	  Mehta	  S,	  Hand	  L,	  Austin	  P,	  et	  al.	  High-­‐frequency	  oscillation	  in	  early	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2013;368(9):795-­‐805.	  
	  	  29	  
41.	   Young	  D,	  Lamb	  S,	  Shah	  S,	  MacKenzie	  I,	  Tunnicliffe	  W,	  Lall	  R,	  et	  al.	  High-­‐frequency	  oscillation	  for	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2013;368(9):806-­‐13.	  
42.	   Terragni	  P,	  Birocco	  A,	  Faggiano	  C,	  Ranieri	  V.	  Extracorporeal	  CO2	  removal.	  Contributions	  to	  nephrology.	  2010;165:185-­‐96.	  
43.	   Terragni	  P,	  Faggiano	  C,	  Ranieri	  V.	  Extracorporeal	  membrane	  oxygenation	  in	  adult	  patients	  with	  acute	  respiratory	  distress	  syndrome.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):86-­‐91.	  
44.	   Hirshberg	  E,	  Miller	  R,	  Morris	  A.	  Extracorporeal	  membrane	  oxygenation	  in	  adults	  with	  acute	  respiratory	  distress	  syndrome.	  Current	  opinion	  in	  critical	  care.	  2013;19(1):38-­‐43.	  
45.	   Terragni	  P,	  Rosboch	  G,	  Tealdi	  A,	  Corno	  E,	  Menaldo	  E,	  Davini	  O,	  et	  al.	  Tidal	  hyperinflation	  during	  low	  tidal	  volume	  ventilation	  in	  acute	  respiratory	  distress	  syndrome.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2007;175(2):160-­‐6.	  
46.	   Bein	  T,	  Weber-­‐Carstens	  S,	  Goldmann	  A,	  Müller	  T,	  Staudinger	  T,	  Brederlau	  J,	  et	  al.	  Lower	  tidal	  volume	  strategy	  (≈3	  ml/kg)	  combined	  with	  extracorporeal	  CO2	  removal	  versus	  'conventional'	  protective	  ventilation	  (6	  ml/kg)	  in	  severe	  ARDS:	  the	  prospective	  randomized	  Xtravent-­‐study.	  Intensive	  care	  medicine.	  2013;39(5):847-­‐56.	  
47.	   Terragni	  P,	  Del	  Sorbo	  L,	  Mascia	  L,	  Urbino	  R,	  Martin	  E,	  Birocco	  A,	  et	  al.	  Tidal	  volume	  lower	  than	  6	  ml/kg	  enhances	  lung	  protection:	  role	  of	  extracorporeal	  carbon	  dioxide	  removal.	  Anesthesiology.	  2009;111(4):826-­‐35.	  
48.	   Pelosi	  P,	  Goldner	  M,	  McKibben	  A,	  Adams	  A,	  Eccher	  G,	  Caironi	  P,	  et	  al.	  Recruitment	  and	  derecruitment	  during	  acute	  respiratory	  failure:	  an	  experimental	  study.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2001;164(1):122-­‐30.	  
49.	   Guérin	  C,	  Reignier	  J,	  Richard	  J-­‐C,	  Beuret	  P,	  Gacouin	  A,	  Boulain	  T,	  et	  al.	  Prone	  positioning	  in	  severe	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2013;368(23):2159-­‐68.	  
	  	  30	  
50.	   Guidet	  B,	  Martinet	  O,	  Boulain	  T,	  Philippart	  F,	  Poussel	  J,	  Maizel	  J,	  et	  al.	  Assessment	  of	  hemodynamic	  efficacy	  and	  safety	  of	  6%	  hydroxyethylstarch	  130/0.4	  vs.	  0.9%	  NaCl	  fluid	  replacement	  in	  patients	  with	  severe	  sepsis:	  The	  CRYSTMAS	  study.	  Critical	  care	  (London,	  England).	  2012;16(3).	  
51.	   Abroug	  F,	  Ouanes-­‐Besbes	  L,	  Elatrous	  S,	  Brochard	  L.	  The	  effect	  of	  prone	  positioning	  in	  acute	  respiratory	  distress	  syndrome	  or	  acute	  lung	  injury:	  a	  meta-­‐analysis.	  Areas	  of	  uncertainty	  and	  recommendations	  for	  research.	  Intensive	  care	  medicine.	  2008;34(6):1002-­‐11.	  
52.	   Sud	  S,	  Friedrich	  J,	  Taccone	  P,	  Polli	  F,	  Adhikari	  N,	  Latini	  R,	  et	  al.	  Prone	  ventilation	  reduces	  mortality	  in	  patients	  with	  acute	  respiratory	  failure	  and	  severe	  hypoxemia:	  systematic	  review	  and	  meta-­‐analysis.	  Intensive	  care	  medicine.	  2010;36(4):585-­‐99.	  
53.	   Papazian	  L,	  Gainnier	  M,	  Marin	  V,	  Donati	  S,	  Arnal	  J-­‐M,	  Demory	  D,	  et	  al.	  Comparison	  of	  prone	  positioning	  and	  high-­‐frequency	  oscillatory	  ventilation	  in	  patients	  with	  acute	  respiratory	  distress	  syndrome.	  Critical	  care	  medicine.	  2005;33(10):2162-­‐71.	  
54.	   Galiatsou	  E,	  Kostanti	  E,	  Svarna	  E,	  Kitsakos	  A,	  Koulouras	  V,	  Efremidis	  S,	  et	  al.	  Prone	  position	  augments	  recruitment	  and	  prevents	  alveolar	  overinflation	  in	  acute	  lung	  injury.	  American	  journal	  of	  respiratory	  and	  critical	  care	  medicine.	  2006;174(2):187-­‐97.	  
55.	   Taccone	  P,	  Pesenti	  A,	  Latini	  R,	  Polli	  F,	  Vagginelli	  F,	  Mietto	  C,	  et	  al.	  Prone	  positioning	  in	  patients	  with	  moderate	  and	  severe	  acute	  respiratory	  distress	  syndrome:	  a	  randomized	  controlled	  trial.	  JAMA	  :	  the	  journal	  of	  the	  American	  Medical	  Association.	  2009;302(18):1977-­‐84.	  
56.	   National	  Heart	  L,	  Blood	  Institute	  Acute	  Respiratory	  Distress	  Syndrome	  Clinical	  Trials	  N,	  Wiedemann	  H,	  Wheeler	  A,	  Bernard	  G,	  Thompson	  B,	  et	  al.	  Comparison	  of	  two	  fluid-­‐management	  strategies	  in	  acute	  lung	  injury.	  The	  New	  England	  journal	  of	  medicine.	  2006;354(24):2564-­‐75.	  
57.	   Sheu	  C-­‐C,	  Gong	  M,	  Zhai	  R,	  Chen	  F,	  Bajwa	  E,	  Clardy	  P,	  et	  al.	  Clinical	  characteristics	  and	  outcomes	  of	  sepsis-­‐related	  vs	  non-­‐sepsis-­‐related	  ARDS.	  Chest.	  2010;138(3):559-­‐67.	  
	  	  31	  
58.	   Myburgh	  J,	  Finfer	  S,	  Bellomo	  R,	  Billot	  L,	  Cass	  A,	  Gattas	  D,	  et	  al.	  Hydroxyethyl	  starch	  or	  saline	  for	  fluid	  resuscitation	  in	  intensive	  care.	  The	  New	  England	  journal	  of	  medicine.	  2012;367(20):1901-­‐11.	  
59.	   Perner	  A,	  Haase	  N,	  Guttormsen	  A,	  Tenhunen	  J,	  Klemenzson	  G,	  Åneman	  A,	  et	  al.	  Hydroxyethyl	  starch	  130/0.42	  versus	  Ringer's	  acetate	  in	  severe	  sepsis.	  The	  New	  England	  journal	  of	  medicine.	  2012;367(2):124-­‐34.	  
60.	   Haase	  N,	  Perner	  A,	  Hennings	  L,	  Siegemund	  M,	  Lauridsen	  B,	  Wetterslev	  M,	  et	  al.	  Hydroxyethyl	  starch	  130/0.38-­‐0.45	  versus	  crystalloid	  or	  albumin	  in	  patients	  with	  sepsis:	  systematic	  review	  with	  meta-­‐analysis	  and	  trial	  sequential	  analysis.	  BMJ	  (Clinical	  research	  ed).	  2013;346.	  
61.	   Schorr	  C,	  Zanotti	  S,	  Dellinger	  R.	  Severe	  sepsis	  and	  septic	  shock:	  management	  and	  performance	  improvement.	  Virulence.	  2014;5(1):190-­‐9.	  
62.	   Dellinger	  R,	  Levy	  M,	  Rhodes	  A,	  Annane	  D,	  Gerlach	  H,	  Opal	  S,	  et	  al.	  Surviving	  Sepsis	  Campaign:	  international	  guidelines	  for	  management	  of	  severe	  sepsis	  and	  septic	  shock,	  2012.	  Intensive	  care	  medicine.	  2013;39(2):165-­‐228.	  
63.	   Silva	  P,	  Pelosi	  P,	  Rocco	  P.	  Fluids	  in	  acute	  respiratory	  distress	  syndrome:	  pros	  and	  cons.	  Current	  opinion	  in	  critical	  care.	  2014;20(1):104-­‐12.	  
64.	   Arroliga	  A,	  Frutos-­‐Vivar	  F,	  Hall	  J,	  Esteban	  A,	  Apezteguía	  C,	  Soto	  L,	  et	  al.	  Use	  of	  sedatives	  and	  neuromuscular	  blockers	  in	  a	  cohort	  of	  patients	  receiving	  mechanical	  ventilation.	  Chest.	  2005;128(2):496-­‐506.	  
65.	   Slutsky	  A.	  Neuromuscular	  blocking	  agents	  in	  ARDS.	  The	  New	  England	  journal	  of	  medicine.	  2010;363(12):1176-­‐80.	  
66.	   Hraiech	  S,	  Forel	  J-­‐M,	  Papazian	  L.	  The	  role	  of	  neuromuscular	  blockers	  in	  ARDS:	  benefits	  and	  risks.	  Current	  opinion	  in	  critical	  care.	  2012;18(5):495-­‐502.	  
67.	   Papazian	  L,	  Forel	  J-­‐M,	  Gacouin	  A,	  Penot-­‐Ragon	  C,	  Perrin	  G,	  Loundou	  A,	  et	  al.	  Neuromuscular	  blockers	  in	  early	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2010;363(12):1107-­‐16.	  
	  	  32	  
68.	   Annane	  D,	  Sébille	  V,	  Bellissant	  E,	  Ger-­‐Inf-­‐05	  Study	  G.	  Effect	  of	  low	  doses	  of	  corticosteroids	  in	  septic	  shock	  patients	  with	  or	  without	  early	  acute	  respiratory	  distress	  syndrome.	  Critical	  care	  medicine.	  2006;34(1):22-­‐30.	  
69.	   Tang	  B,	  Craig	  J,	  Eslick	  G,	  Seppelt	  I,	  McLean	  A.	  Use	  of	  corticosteroids	  in	  acute	  lung	  injury	  and	  acute	  respiratory	  distress	  syndrome:	  a	  systematic	  review	  and	  meta-­‐analysis.	  Critical	  care	  medicine.	  2009;37(5):1594-­‐603.	  
70.	   Thompson	  B.	  Corticosteroids	  for	  ARDS.	  Minerva	  anestesiologica.	  2010;76(6):441-­‐7.	  
71.	   Rhen	  T,	  Cidlowski	  J.	  Antiinflammatory	  action	  of	  glucocorticoids-­‐-­‐new	  mechanisms	  for	  old	  drugs.	  The	  New	  England	  journal	  of	  medicine.	  2005;353(16):1711-­‐23.	  
72.	   Liu	  L,	  Wang	  Y,	  Zhou	  J,	  Long	  F,	  Sun	  H,	  Liu	  Y,	  et	  al.	  Rapid	  non-­‐genomic	  inhibitory	  effects	  of	  glucocorticoids	  on	  human	  neutrophil	  degranulation.	  Inflammation	  research	  :	  official	  journal	  of	  the	  European	  Histamine	  Research	  Society	  	  [et	  al].	  2005;54(1):37-­‐41.	  
73.	   Stahn	  C,	  Buttgereit	  F.	  Genomic	  and	  nongenomic	  effects	  of	  glucocorticoids.	  Nature	  clinical	  practice	  Rheumatology.	  2008;4(10):525-­‐33.	  
74.	   Steinberg	  K,	  Hudson	  L,	  Goodman	  R,	  Hough	  C,	  Lanken	  P,	  Hyzy	  R,	  et	  al.	  Efficacy	  and	  safety	  of	  corticosteroids	  for	  persistent	  acute	  respiratory	  distress	  syndrome.	  The	  New	  England	  journal	  of	  medicine.	  2006;354(16):1671-­‐84.	  
75.	   Hough	  C,	  Steinberg	  K,	  Taylor	  Thompson	  B,	  Rubenfeld	  G,	  Hudson	  L.	  Intensive	  care	  unit-­‐acquired	  neuromyopathy	  and	  corticosteroids	  in	  survivors	  of	  persistent	  ARDS.	  Intensive	  care	  medicine.	  2009;35(1):63-­‐8.	  
76.	   Meduri	  G,	  Marik	  P,	  Chrousos	  G,	  Pastores	  S,	  Arlt	  W,	  Beishuizen	  A,	  et	  al.	  Steroid	  treatment	  in	  ARDS:	  a	  critical	  appraisal	  of	  the	  ARDS	  network	  trial	  and	  the	  recent	  literature.	  Intensive	  care	  medicine.	  2008;34(1):61-­‐9.	  
77.	   Hughes	  C,	  McGrane	  S,	  Pandharipande	  P.	  Sedation	  in	  the	  intensive	  care	  setting.	  Clinical	  pharmacology	  :	  advances	  and	  applications.	  2012;4:53-­‐63.	  
	  	  33	  
78.	   McGrane	  S,	  Pandharipande	  P.	  Sedation	  in	  the	  intensive	  care	  unit.	  Minerva	  anestesiologica.	  2012;78(3):369-­‐80.	  
79.	   Jakob	  S,	  Ruokonen	  E,	  Grounds	  R,	  Sarapohja	  T,	  Garratt	  C,	  Pocock	  S,	  et	  al.	  Dexmedetomidine	  vs	  midazolam	  or	  propofol	  for	  sedation	  during	  prolonged	  mechanical	  ventilation:	  two	  randomized	  controlled	  trials.	  JAMA	  :	  the	  journal	  of	  the	  American	  Medical	  Association.	  2012;307(11):1151-­‐60.	  
80.	   Nakamura	  T,	  Sato	  E,	  Fujiwara	  N,	  Kawagoe	  Y,	  Maeda	  S,	  Yamagishi	  S-­‐i.	  Increased	  levels	  of	  soluble	  receptor	  for	  advanced	  glycation	  end	  products	  (sRAGE)	  and	  high	  mobility	  group	  box	  1	  (HMGB1)	  are	  associated	  with	  death	  in	  patients	  with	  acute	  respiratory	  distress	  syndrome.	  Clinical	  biochemistry.	  2011;44(8-­‐9):601-­‐4.	  
81.	   Roumen	  R,	  Hendriks	  T,	  van	  der	  Ven-­‐Jongekrijg	  J,	  Nieuwenhuijzen	  G,	  Sauerwein	  R,	  van	  der	  Meer	  J,	  et	  al.	  Cytokine	  patterns	  in	  patients	  after	  major	  vascular	  surgery,	  hemorrhagic	  shock,	  and	  severe	  blunt	  trauma.	  Relation	  with	  subsequent	  adult	  respiratory	  distress	  syndrome	  and	  multiple	  organ	  failure.	  Annals	  of	  surgery.	  1993;218(6):769-­‐76.	  
82.	   Donnelly	  T,	  Meade	  P,	  Jagels	  M,	  Cryer	  H,	  Law	  M,	  Hugli	  T,	  et	  al.	  Cytokine,	  complement,	  and	  endotoxin	  profiles	  associated	  with	  the	  development	  of	  the	  adult	  respiratory	  distress	  syndrome	  after	  severe	  injury.	  Critical	  care	  medicine.	  1994;22(5):768-­‐76.	  
83.	   Meade	  P,	  Shoemaker	  W,	  Donnelly	  T,	  Abraham	  E,	  Jagels	  M,	  Cryer	  H,	  et	  al.	  Temporal	  patterns	  of	  hemodynamics,	  oxygen	  transport,	  cytokine	  activity,	  and	  complement	  activity	  in	  the	  development	  of	  adult	  respiratory	  distress	  syndrome	  after	  severe	  injury.	  The	  Journal	  of	  trauma.	  1994;36(5):651-­‐7.	  
84.	   van	  der	  Heijden	  M,	  van	  Nieuw	  Amerongen	  G,	  Chedamni	  S,	  van	  Hinsbergh	  V,	  Johan	  Groeneveld	  A.	  The	  angiopoietin-­‐Tie2	  system	  as	  a	  therapeutic	  target	  in	  sepsis	  and	  acute	  lung	  injury.	  Expert	  opinion	  on	  therapeutic	  targets.	  2009;13(1):39-­‐53.	  
85.	   Xing	  K,	  Murthy	  S,	  Liles	  W,	  Singh	  J.	  Clinical	  utility	  of	  biomarkers	  of	  endothelial	  activation	  in	  sepsis-­‐-­‐a	  systematic	  review.	  Critical	  care	  (London,	  England).	  2012;16(1).	  
86.	   Gallagher	  D,	  Parikh	  S,	  Balonov	  K,	  Miller	  A,	  Gautam	  S,	  Talmor	  D,	  et	  al.	  Circulating	  angiopoietin	  2	  correlates	  with	  mortality	  in	  a	  surgical	  population	  with	  
	  	  34	  
acute	  lung	  injury/adult	  respiratory	  distress	  syndrome.	  Shock	  (Augusta,	  Ga).	  2008;29(6):656-­‐61.	  
87.	   Wada	  T,	  Jesmin	  S,	  Gando	  S,	  Yanagida	  Y,	  Mizugaki	  A,	  Sultana	  S,	  et	  al.	  The	  role	  of	  angiogenic	  factors	  and	  their	  soluble	  receptors	  in	  acute	  lung	  injury	  (ALI)/	  acute	  respiratory	  distress	  syndrome	  (ARDS)	  associated	  with	  critical	  illness.	  Journal	  of	  inflammation	  (London,	  England).	  2013;10(1):6.	  
88.	   Fremont	  R,	  Koyama	  T,	  Calfee	  C,	  Wu	  W,	  Dossett	  L,	  Bossert	  F,	  et	  al.	  Acute	  lung	  injury	  in	  patients	  with	  traumatic	  injuries:	  utility	  of	  a	  panel	  of	  biomarkers	  for	  diagnosis	  and	  pathogenesis.	  The	  Journal	  of	  trauma.	  2010;68(5):1121-­‐7.	  
 
	  	  35	  
Bibliography 
 Corey Kull was born in Oakville Ontario and grew up in Belleville. With a 
long standing passion for science he completed an honours bachelor degree in 
Human Kinetics at the University of Guelph in Ontario. Shortly after he persued 
his interest in medicine at the University Of Zagreb, where Anesthesiology and 
Intensive Care Medicine became his primary interests.  
